NCT04696016

Guiding Sufentanil Administration With Skin Conductance in Mechanically Ventilated Intensive Care Patients

Status unknown NA Last updated 3 February 2021

What this trial tests

NA trial testing Skin conductance guided antinociception in Nociceptive Pain in 30 participants. Status unknown.

Timeline

1 February 2021

Primary endpoint
30 July 2021

30 July 2021

Quick facts

Lead sponsor	Erasme University Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	1 February 2021
Primary completion	30 July 2021
Estimated completion	30 July 2021

Drugs / interventions tested

• Skin conductance guided antinociception
• Standard care antinociception

Conditions studied

• Nociceptive Pain — all drugs for Nociceptive Pain →

Sponsor

Erasme University Hospital

Who can join

Adults 18 to 100, any sex, with Nociceptive Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Opioid administration in mechanically ventilated patients in the intensive care unit (ICU) is essential to maintaining patient respiratory and hemodynamic stability. Mechanical ventilation is a persistently nociceptive event that can continuously causes discomfort in the trachealy intubated patient. This can lead to patient-ventilator dyssynchrony, tachycardia, hypertension, and their associated complications. Opioids blunt respiratory drive, which facilitates mechanical ventilation, and decrease the sympathetic response to nociception. However, excessive opiate administration is associated with many adverse events, including respiratory depression, delirium, ileus, nausea, and vomiting. Currently, the standard administration in our institution of sufentanil, a potent opiate, consists of continuous infusions of 0.15µg/kg/h to 0.3µg/kg/h.

Mechanically ventilated patients are unable to speak and are often sedated. This greatly impacts the patient's capacity to communicate pain. The use of a nociceptive monitor may be a possible solution. Skin conductance monitoring (Pain Monitor, Med-Storm, Norway), measures the peaks per second of electrical conduction. This non hemodynamic monitor uses skin conduction as a surrogate to nociception (i.e., the patient's unconscious response to a noxious stimulus). It may consequently guide opioid administration in ICU patients towards and avoid the consequences of excessive or inadequate antinociception.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.